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Abstract
Background: Several methods have been used to induce somatic cells to re-enter the pluripotent state. Viral transduction of
reprogramming genes yields higher efficiency but involves random insertions of viral sequences into the human genome.
Although induced pluripotent stem (iPS) cells can be obtained with the removable PiggyBac transposon system or an
episomal system, both approaches still use DNA constructs so that resulting cell lines need to be thoroughly analyzed to
confirm they are free of harmful genetic modification. Thus a method to change cell fate without using DNA will be very
useful in regenerative medicine.
Methodology/Principal Findings: In this study, we synthesized mRNAs encoding OCT4, SOX2, cMYC, KLF4 and SV40 large T
(LT) and electroporated them into human fibroblast cells. Upon transfection, fibroblasts expressed these factors at levels
comparable to, or higher than those in human embryonic stem (ES) cells. Ectopically expressed OCT4 localized to the cell
nucleus within 4 hours after mRNA introduction. Transfecting fibroblasts with a mixture of mRNAs encoding all five factors
significantly increased the expression of endogenous OCT4, NANOG, DNMT3b, REX1 and SALL4. When such transfected
fibroblasts were also exposed to several small molecules (valproic acid, BIX01294 and 59-aza-29-deoxycytidine) and cultured
in human embryonic stem cell (ES) medium they formed small aggregates positive for alkaline phosphatase activity and
OCT4 protein within 30 days.
Conclusion/Significance: Our results demonstrate that mRNA transfection can be a useful approach to precisely control the
protein expression level and short-term expression of reprogramming factors is sufficient to activate pluripotency genes in
differentiated cells.
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Introduction
An approach to reprogram cell fate without genetic modifica-
tion would be very useful for regenerative medicine. Currently,
most methodologies go through DNA-based routes, with foreign
genetic materials either permanently left in the genome of resulting
cells, or later removed or lost after multiple rounds of cell division.
In all the cases, stringent genome wide tests are needed to confirm
the absence of potentially harmful insertional mutagenesis [1,2].
Protein transduction of recombinant transcription factors has been
used for reprogramming [3], but proteins produced in bacteria
may be mis-folded and lack essential modifications that only occur
in mammalian cells, so that their in vivo functionality may be
compromised. Kim and colleagues reported the generation of
human iPS cells by incubating fibroblasts with lysates from HEK
293T cells expressing recombinant OCT4, SOX2, KLF4 and
cMYC [4]. However, cell lysates contain many poorly defined
factors that could also be taken up by the reprogrammed cells and
give unpredictable consequences. Thus this method will be
difficult to implement in clinical settings. While chemical
compounds have been used to regulate cell fate or alter DNA
and chromatin modifications, to date, no reprogramming or trans-
differentiation has been achieved by small molecules alone [5].
An mRNA-based approach could offer several advantages: first,
it does not lead to any genetic modification of the host genome.
mRNAs are directly translated into functional proteins in the
cytoplasm with proper mammalian post-translational modifica-
tions which would result in much higher functionality than
recombinant proteins produced in the bacteria. Second, mRNAs
are much smaller than DNAs, and as single strand nucleic acids
without any flanking plasmid sequences they can be introduced
into cells with higher efficiency and much lower cytotoxicity. It is
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14397
also easier to combine several different mRNAs and to control
their dosage than using multiple or multi-cistronic DNA
constructs. An obvious disadvantage of mRNAs is that they are
degraded by the cell in 2-3 days so that the expression window is
very short. Nevertheless, an mRNA based approach could be a
useful means to regulate cellular function, and to mediate trans-
differentiation such as from fibroblast to neurons or cardiomyo-
cytes [6,7] that require shorter time.
mRNA transfection has been used in hematopoietic progenitor
cells, mesenchymal stroma cells, antigen presenting dendritic cells
and lymphocytes [8,9,10,11]. Activated B cells transfected with
mRNAs encoding co-stimulatory molecules, cytokines and antigen
showed enhanced proliferation and were able to induce antigen-
specific cytotoxic T lymphocyte responses [10]. dendritic cells
transfected with mRNAs of viral antigen stimulated robust and
specific T cell response [12]. Moreover, in a phase I/II clinical
trial of dendritic cells vaccine, autologous dendritic cells loaded
with autologous melanoma mRNA as tumor antigen produced
vaccine specific response in the majority of patients [13]. This trial
also showed that cells transfected with mRNA are safe for use in
patients.
In the present study, we set out to test the feasibility of using
mRNA to induce pluripotency. We found that microporation is
highly effective for mRNA transfection. Moreover, transient
expression of OCT4, SOX2, KLF4, cMYC and LT together
with small molecule treatment significantly increased the expres-
sion of embryonic stem cell specific genes in fibroblast cells.
Methods
Ethics Statement
HuF1 (XX) was derived from an abortus obtained from a
patient undergoing 1st trimester fetal termination using Mefipris-
tone. The project was approved by the South Sheffield Research
Ethics Committee (SSREC) and a fully informed patient consent
(written) was obtained according to local and national guidelines.
Cell culture
Three human fibroblast lines were used in this study. HuF1
(XX, passage 4) is a human fetal skin fibroblast cell line (source
described above). The derivation procedure was as follows: fetal
skin was recovered and chopped in to small pieces in DMEM
medium supplemented with 15% fetal calf serum. An outgrowth of
fibroblast cells proliferated to confluency and were passaged to
passage 4 using trypsin-EDTA before being cryopreserved in 10%
DMSO in FCS. MRC5 (ATCC, CCL-171, XY, passage 15) is a
human embryonic lung fibroblast line and HFF (ATCC CRL-
2429, XY, passage 4) was derived from human foreskin. Human
fibroblast cells were maintained in DMEM 10% FCS, 10% CO2.
After transfection of reprogramming factors, they were seeded on
gelatin coated flasks (BD), cultured in MEF conditioned human
embryonic stem cell medium (HES Medium) containing 20%
Knock-out serum replacement (KSR) [14] and 8 ng/ml of FGF2.
In some cases 200 mM valproic acid (Merck), 1 mM BIX01294
(Tocris) and 0.5 mM 5-aza-29-deoxycytidine (Sigma) were includ-
ed.
Cloning and mRNA in vitro transcription
cDNAs encoding OCT4, SOX2, KLF4,cMYCwere cloned from
human ES cells using the One-step RT-PCR kit (Invitrogen). SV40
large T cDNA was a generous gift from Dr. Robert Weinberg. The
identity of each gene was confirmed by sequencing. The coding
regions were all inserted into the RN3P plasmid between a T3 RNA
polymerase promoter and a recombinant polyA tail [15]. For
mRNA in vitro transcription, the plasmids were linearized with Sfi
I, and the capped mRNAs were synthesized using an AmpliCap-
Max T3 High Yield Message Maker kit (Epicentre).
Electroporation
Human fibroblast cells, keratinocytes and neural stem cells were
electroporated using a Microporator Neon (Invitrogen), using pre-
optimized parameters – herein referred to as ‘microporation’.
Following microporation, cells were transferred into pre-warmed
fibroblast medium (DMEM with 10% FCS). Next day, the
medium was replaced with MEF conditioned HES medium
supplemented with FGF2 (8 ng/ml). In some experiments,
valproic acid (0.2 mM) (Merck), BIX01294 (1 mM) (Tocris) and/
or 5-aza-29-deoxycytidine (0.5 mM) (Sigma) were also added.
Western blot
The following antibodies are used: OCT4 (Santa Cruz, sc-
5279), NANOG (R&D systems, AF1997), SOX2 (Chemicon,
AB5603), cMYC (Santa Cruz, sc-764), KLF4 (Santa Cruz,
sc20691), LIN28 (R&D systems, AF3757). Cells were trypsinized,
washed with PBS three times and lysed in sample loading buffer
(0.125 M Tris-HCl, pH=6.8, 4% SDS, 20% Glycerol, 0.002%
Bromophenol Blue). 26105 cells equivalent lysate was loaded per
lane.
Reverse transcription and Q-PCR
RNA was extracted with TRIZOL (Invitrogen). Q-PCRs were
carried out with SYBR Green JumpStartTM Kit on a Bio-Rad
iCycler. The sequences of the primers used are listed in Table S1.
Figure 1. Schematic view of experiment strategy.
doi:10.1371/journal.pone.0014397.g001
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Figure 2. Efficient transfection of GFP mRNA into human fibroblast cells. (A) FACS histogram of GFP positive cells after GFP mRNA or DNA
transfection (b and d). Non-transfected cells (a and c). (B) GFP mRNA and DNA transfected cells. BF brightfield. (C) Histogram and table of GFP positive
cells after microporation of 0, 5, 10 and 20 mg of mRNA. (D) Percentage of GFP positive cells over 12 days following mRNA or DNA transfection.
doi:10.1371/journal.pone.0014397.g002
Reprogram Cell Fate by mRNA
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14397
Immunostaining and alkaline phosphatase (ALP) assay
For immunostaining, cells were fixed with 4% PFA and stained
with OCT4 antibody followed by Alex488 conjugated 2nd Ab.
ALP assay was performed using the ALP substrate solution (Sigma
AR0100 and AR0200) according to manufacturer’s instruction.
Results
Producing mRNAs of reprogramming factors with
recombinant 59 and 39 UTRs
To generate mRNAs of reprogramming factors efficiently, we
employed RN3P vector that contains the 59 and 39 UTRs of Xenopus
b-globin flanking the multiple cloning sites (MCS) [15]. The 59UTR
contains the ribosomal binding site to enhance translation initiation
and the 39UTR can stabilizes the mRNA (Fig. 1). The coding
sequences of OCT4, SOX2, KLF4, cMYC and SV40LT were
inserted between the Bgl II and Not I sites. The plasmids were first
linearized with Sfi I, and T3 RNA polymerase was used to
transcribe mRNAs.
Efficient transfection of human fibroblast cells with
mRNA by microporation
To establish a method to introduce mRNA into human fibroblast
cells, we utilized the Neon Transfection system (Invitrogen). We
Figure 3. Protein expression following mRNA transfection. (A) OCT4-RFP localizes into nucleus in fibroblast cells. (B) FACS analysis of OCT4
protein expression 24 hrs after mRNA microporation. Cy3 conjugated secondary antibody was used. (C)Western blot showing corresponding protein
expression in 106 MRC5 cells transfected with OCT4 (17 mg), SOX2 (10 mg), cMYC (6 mg), KLF4 (6.5 mg), SV40LT (3.5 mg). The negative control is GFP
mRNA transfected MRC5 cells. HUES1 is human ES cells.
doi:10.1371/journal.pone.0014397.g003
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found that by optimizing electroporation parameters, we could
consistently obtain nearly 100% transfection efficiency with GFP
mRNA in MRC5 cells, while only 50–60% cells are positive for
GFP after DNA plasmid microporation (Fig. 2A). mRNA has
significant lower cytotoxicity compared to DNA, as we observed 2–
3 times more cells survived after mRNA microporation than after
DNA transfection (data not shown). Increasing the amount of
mRNA used for transfection led to a corresponding increase in the
median fluorescence intensity quantified by flow cytometry, while
the percentage of the cells positive for GFP was still close to 100%
(Fig. 2D). We also monitored the duration of GFP expression. More
than 95% of MRC5 cells expressed GFP one and two days after
microporation, whereas the percentage decreased sharply from day
3 and reached background levels by day 5. The percentage of GFP
positive cells after DNA microporation was close to 60% in day 1
and 2, then decreased gradually during the following days (Fig. 2D).
To confirm that the ectopically expressed reprogramming
factors correctly localize as the endogenous protein, we generated
a vector encoding OCT4 fused to the fluorescent protein mCherry
[16]. Four hours after mRNA transfection, we could detect most
OCT4-cherry protein in the nucleus (Fig. 3A). Moreover, the
immunoflurescence of ectopically expressed OCT4 co-related with
the amount of mRNA transfected (Fig. 3B). It is critical that the
protein levels of ectopically expressed reprogramming factors were
comparable to that of the ES cells. During the first two days after
mRNA transfection, higher amount of OCT4, SOX2 and KLF4
protein were detected in MRC5 cells than that in human ES cells,
while cMYC proteins were similar (Fig. 3C). However, the level of
ectopically expressed protein decreased significantly at day 3 and
became undetectable at day 4. GFP mRNA transfected fibroblast
cells had low level of cMYC, while OCT4, SOX2 and KLF4 were
undetectable. Taken together, these data demonstrate that mRNA
microporation has the advantage of low cytotoxicity, high
efficiency and an ability to control precisely the protein expression
level by varying the dosage, while the disadvantage of the
approach is the short expression window with the peak expression
lasting only about two days.
Individual reprogramming factors differentially affect
fibroblast survival and proliferation
As the expression level of individual reprogramming factors has
been shown to be important for efficient reprogramming [17], we
next tested the effect of each factor on cell growth following
mRNA transfection. HFF were used in this series of experiments.
Aliquots of 105 fibroblast cells were individually microprorated
with 5 mg of GFP, OCT4, SOX2, KLF4, cMYC or SV40LT
mRNAs, after which the cells were seeded into 6-well plates, and
cell numbers were counted three and four days later. SV40LT was
Figure 4. Cell survival study following mRNA transfection. (A) Morphology of cells transfected with each reprogramming factor. (B–a) Bar
graph of cell number 3 and 4 days after mRNA transfection. Note that SOX2 group has much fewer cells than other groups. (B–b) Growth curve of
MRC5 cells undergone microporation but no mRNA was added.
doi:10.1371/journal.pone.0014397.g004
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chosen because it has been shown to improve the efficiency and
pace of reprogramming[2,18], although it may also increase the
risk of tumorigenecity due to its ability to inhibit p53 function
[19,20,21,22,23,24,25]. Among all the factors, we noticed that
SOX2 significantly reduced cell proliferation: by day 3, OCT4,
KLF4, cMYC and SV40LT transfected fibroblasts grew to 60–
80% confluence, while SOX2 transfected cells were markedly less
confluent (Fig. 4A–c). Cell counts showed that OCT4, KLF4,
cMYC and SV40LT groups all had more than 35,000 cells, while
there were only approximately 5,000 cells in SOX2 group
(Fig. 4B). The GFP group had approximately 10,000 cells,
indicating over-expression of GFP also had a detrimental effect
on HFF fibroblast cell growth (Fig. 4B). On day 4, most groups
reached 90% confluency except GFP and SOX2. We also
analyzed the cell cycle profile by propidium iodide (PI) staining
on day 3 and day 4. The SOX2 group had 43% of cells in S-phase
on day 4, significantly higher than cells from other groups (Fig. 5A–
e and B–b). This may be due to active cell cycle progression after
SOX2 protein diminished from day 3. Although SOX2 showed a
negative impact on cell cycle progression, as it is the co-factor for
OCT4, substantial reduction of SOX2 mRNA would not be
favorable for reprogramming, thus in our experiments, we used
the following amounts of mRNA: OCT4:SOX2:KLF4:c-
MYC:SV40LT (OSKMT) = 18:9:6:6:3 (mg/million cells), The
KLF4 and cMYC mRNAs were one third of OCT4 mRNA, as
this appeared to be the optimal ratio for reprogramming [17].
Expression reprogramming factors by mRNA transfection
can activate pluripotency marker genes
During somatic nuclear transfer and cell fusion experiments,
pluripotency genes OCT4 and NANOG can be activated within
2–3 days [26,27]. To test whether transient expression of
reprogramming factors can activate ES cell specific genes, we
microporated OSKMT mRNAs into HuF1 fibroblasts and
performed quantitative RT-PCR, three and seven days after
mRNA transfection in HuF1. Reverse primers specific for the
endogenous OCT4 39UTR were used to distinguish endogenous
OCT4 from ectopic OCT4 mRNA. Three days after transfection,
we detected significant up-regulation of ES cell marker genes
OCT4, NANOG, REX1, DNMT3b and SALL4, with OCT4
increased more than two fold and NANOG more than five fold
(Fig. 6A). On day seven, we detected further elevation in
Figure 5. SOX2 reduced fibroblast proliferation. (A) Histogram of PI staining. The mRNA transfected were as indicated. First red peak, G0/G1
phase. Second red peak, G2/M phase. White and blue area, S phase. (B) Bar graph presentation of cell cycle profile after each mRNA transfection. The
genes were indicated at the bottom. There was significantly higher percentage of S phase cells in SOX2 group on day 4 (red star).
doi:10.1371/journal.pone.0014397.g005
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endogenous OCT4 level. On the other hand, the levels of
NANOG, REX1, DNMT3b and SALL4 decreased compared to
day three (Fig. 6A).
It has been shown that the HDAC inhibitor valproic acid, the
histone methyltransferase inhibitor BIX01294 and the DNA
methyltransferase inhibitor 59-azacytidine (59-AzaC) significantly
increased the efficiency of iPS cells generation in viral transduction
methods [28,29,30]. In our preliminary test, 59-AzaC showed
significant cytotoxicity to human fibroblast cells possibly due to
inhibition of protein synthesis [31]. Therefore, we used 59-aza-29-
deoxycytidine that causes DNA demethylation more specifically
[32]. We next examined whether combining these small molecules
with mRNAs of reprogramming factors could enhance the
activation of pluripotency-associated genes. HuF1 cells were first
microporated with the mRNA cocktail, 24 hours later, the
medium was changed to human ES cell medium supplemented
with valproic acid (200 mM), BIX01294 (1 mM) and 5-aza-29-
deoxycytidine (0.5 mM). After another 48 hours, cells were lysed
and subjected to RT-PCR analysis. Indeed, a more than 10 fold
increase in endogenous OCT4 and NANOG transcripts were
detected in OSKMT mRNA plus small molecules (SM) treated
cells compared with cells transfected with GFP and treated with
DMSO only (Fig. 6B). These results indicate that these chemicals
that influence chromatin structure can enhance the effects of
short-term expression of key reprogramming factors in activating
expression of the endogenous pluripotency associated transcription
factor network.
Complete reprogramming of human fibroblast cells to plurip-
otent stem cells usually takes three to four weeks [33,34]. To test
whether transient expression of OSKMT plus treatment with
DNA and chromatin modifying compounds can lead to stable
embryonic stem cell-like transformation after long-term culture,
MRC5 human fibroblast cells were first microporated with the
mRNA cocktail. Twenty four hours after microporation, the
medium was changed to MEF conditioned HES medium
containing BIX01294, valproic acid, and 5-aza-29-deoxycytidine,
for a further 48 hours. Afterwards, cells were cultured in MEF
conditioned HES medium without any chemical compounds until
confluent, approximately two weeks. Then they were passaged
onto gelatin coated flasks and fed with MEF conditioned human
ES medium. Some small cell aggregates became visible three
weeks after microporation. However, these aggregates grew very
slowly and could not be passaged. Some of the aggregates in the
OSKMT plus small molecule treatment group were strongly
positive for alkaline phosphatase, a marker for the ES/iPS cell
(Figure 7A–f), whereas only faintly AP positive colonies were
present in OSKMT mRNA treated group (Figure 7A–e). A small
number of the aggregates in the OSKMT plus small molecule
group could also be stained for OCT4 protein expression
(Figure 7B–h), whereas none of the aggregates from small
molecule or OSKMT treatment groups alone expressed OCT4.
Multiple rounds of mRNA transfection and small molecule
treatment were attempted, but in all instances very few cells
survived, and typically senesced within a week after treatment.
Reprogramming by mRNA and Small Molecules Caused
Cell Cycle Arrest
Induction of pluripotency in somatic cells needs to overcome the
barrier imposed by DNA damage repair machinery
[19,20,21,22,23,24,25]. The reason that the apparently repro-
grammed cells that we observed in our experiments failed to
proliferate could have been due to cell cycle arrest following a
DNA damage response. To test this, several cell aggregates in
OSKMT plus small molecule group were manually picked 4 weeks
after transfection and subjected to RT-PCR analysis. p21, a target
of p53 and an inhibitor of cell cycle progression, was significantly
up-regulated in cell aggregates compared with in HUES1 ES cells
and fibroblast cells transfected with GFP (Fig. 8A), while 48 hrs
treatment with any of the small molecules did not lead to any
substantial change in these genes (Fig. 8B) This suggests that while
transient OSKMT expression combined with small molecule
treatment induced a certain degree of reprogramming, it also
triggered DNA damage response and cell cycle arrest.
Discussion
In this study, we have developed a protocol to efficiently
introduce mRNAs encoding OCT4, SOX2, KLF4, cMYC and
LT into human fibroblast cells. Moreover, we showed that the
level of protein expression tightly correlates with the amount of
input mRNA. mRNA exhibited much higher transfection
efficiency and less cytotoxicity than DNA. We observed less cell
death in fibroblast cells transfected with 40 mg of mRNA than 3 mg
of plasmid DNA (data not shown). Over expression of OCT4
promoted cell proliferation while SOX2 alone seemed to have
opposite effect. In the light of the cell cycle studies, we modified
the ratio of mRNAs to reduce the negative impact of SOX2. Our
results suggest that it is possible to combine mRNA factors of
different concentrations to create an optimized reprogramming
mix to improve reprogramming efficiency.
Transfection of mRNA encoding five reprogramming factors
can activate normally silenced embryonic genes within a few days.
This result is in agreement with several recently published studies.
Figure 6. Activation of embryonic stem cell specific genes by
mRNA transfection and small molecule treatment. (A) Relative
expression level of ES cell specific gene (as noted) 3 and 7 days post
mRNA transfection. The expression levels of these genes in fibroblast
cells transfected with GFP mRNA were considered as 1. All the genes
were normalized against the GAPDH level.
doi:10.1371/journal.pone.0014397.g006
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In cell fusion experiments, pluripotency genes began to express
within one to two days following somatic cells fusion with ES cells
even in the absence of SOX2 [35,36,37,38]. OCT4 and NANOG
demethylation occurred just one day after fusion [27]. When a
somatic nucleus was place into a mouse zygote, the OCT4 gene
was activated after only two cell cycles [26]. These reports together
with ours suggest that given sufficient amount of reprogramming
factors, the de-differentiation process can be initiated rather
rapidly. This therefore raises the question of why iPS cells can only
be obtained after stable expression of defined factors for 3–4
weeks, while an enucleated oocyte can reprogram somatic nucleus
within a few days [39]? In addition to OCT4, SOX2, KLF4 and
cMYC, enucleated oocytes contain many regulators of chromatin
modification, cell cycle and DNA damage response [40], which
may be responsible for their robust reprogramming ability.
Indeed, oocyte factors such as activation-induced cytidine
deaminase (AID) and histone demethylase Jhdm2a can demeth-
ylate DNA and histones respectively and are required for
reprogramming through the ES cell fusion method [27,35]. It is
possible that by adding the proper amount of ‘‘helper’’ factors to
the Yamanaka 4-factor or Thomson 4-factor [33,34], the
reprogramming process can be significantly accelerated.
Small molecules that can erase somatic chromatin and DNA
modifications have been shown to greatly improve the repro-
gramming efficiency from mouse fibroblast cells [28,30]. The
small molecule BIX-01294, an inhibitor of the G9a histone
methyltransferase, when combined with OCT4 and KLF4,
reprogrammed neural stem cells more efficiently than using
OCT4, KLF4 and cMYC [30]. While HDAC inhibitor valproic
acid, improves reprogramming efficiency by more than 100-fold
[28]. We found that brief treatment with 5-aza-29-deoxycytidine,
BIX-01294 and valproic acid following mRNA transfection
further increased the activation of pluripotency genes than mRNA
transfection alone. However, during our attempt of multiple
rounds of microporation transfection, such treatment caused
massive cell death. Although colonies positive for AP and OCT4
appeared following just one round of mRNA transfection and
small molecule treatment, these cells still activated high levels of
p21 and failed to expand. Thus, additional chemical compounds
that support cell survival or relieve DNA damage response will be
Figure 7. Expression of ES markers in mRNA reprogrammed cells. (A) AP positive colonies from OSKMT or OSKMT and SM treated fibroblast
cells. Arrow pointing to an ES cell like colony with strong AP activity (f). (B). OSKMT and SM treated fibroblast cells expressed OCT4 (h. arrow) while
small molecule (SM) treated cells did not (e). SHEF5 human ES cells were used as positive control. OCT4 in green and DNA in blue.
doi:10.1371/journal.pone.0014397.g007
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beneficial for generating iPS cells using mRNA and small molecule
approach. Caution should also be taken while using these reagents.
For example, SV40LT is known to inhibit tumor suppressor p53
function and cause cancer-like cellular transformation [41]. Use of
genes or compounds to inhibit DNA damage in order to facilitate
reprogramming may increase the risk of tumorigenicity of
resulting iPS cells.
Recently, there were two reports on using mRNA generate iPS
cells. Yakubov and colleagues obtained similar AP positive
colonies as us, however, no differentiation analysis were done,
thus it is hard to evaluate the pluripotency of their iPS cells [42].
Angel and Yanik found that long RNA transfection activated
innate immunity that caused significant cell death [43]. Their
result is in agreement with our observation that repeated mRNA
transfection resulted in cell growth arrest and death.
In summary, our results demonstrate that by optimizing the
combination and dosage of mRNA and small molecules, it is
possible to reprogram cell fate without using any DNA. This
strategy could be exploited to generate cells with therapeutic
values. Recently, it was shown that fibroblast cells can be
reprogrammed to neurons by defined factors within 3–5 days
[7]. Adenovirus transduction of NGN3, PDX1 and MAFA in
adult pancreas led to appearance of new insulin secreting cells
after 3 days, indicating trans-differentiation from exocrine b cells
to endocrine is a relatively fast process [44]. These time windows
fall into the range that can be fulfilled by mRNA transfection
which is 2-3 days. While our manuscript was in revision, Warren
et al successfully generated human iPS cells using mRNA [45].
The key to their success is to suppress interferon response triggered
by repeated mRNA transfection. mRNA has the advantage of
high transfection efficiency, controllability and avoidance of
genetic modification. Once the innate immune response activated
by introducing large amount of long RNAs can be overcome, it
will be a very useful approach for cellular reprogramming.
Supporting Information
Table S1 Q-PCR primers.
Found at: doi:10.1371/journal.pone.0014397.s001 (0.03 MB
DOC)
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